What You Should Know:
- Ubie, a global healthcare AI platform, and the American Kidney Fund (AKF), a leading kidney disease non-profit, have joined forces to improve early detection of kidney disease.
- This strategic collaboration aims to leverage Ubie's AI-powered Symptom Checker and AKF's expertise to empower patients and accelerate diagnosis.
Why Early Diagnosis Matters
Kidney disease is a major health concern, affecting millions in the US. Chronic kidney disease
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Abbott Unveils FreeStyle Libre 3 Plus: World’s Smallest CGM Sensor with Future AID Compatibility
What You Should Know:
- At the American Diabetes Association conference, Abbott unveiled a new addition to its FreeStyle Libre portfolio – the FreeStyle Libre 3 Plus sensor.
- The sensor boasts the distinction of being the world's smallest, thinnest, and most discreet continuous glucose monitoring (CGM) sensor available.
Unmatched Design and Performance
The FreeStyle Libre 3 Plus sensor offers a unique combination of user-centric features:
Unmatched Discreetness: The
Read More
Teladoc Health’s AI Scores Big in Diabetes Management: Personalized Nudges and Coaching Boost Patient Engagement and Outcomes
What You Should Know:
- Teladoc Health (NYSE:TDOC), a leader in virtual healthcare, presented compelling new data at the American Diabetes Association's 84th Scientific Sessions. The findings showcase the effectiveness of Teladoc Health's AI-powered approach to managing type 2 diabetes.
- The study focused on the impact of personalized health nudges on patients identified as at-risk for uncontrolled diabetes through mobile devices
AI-Driven Nudges Lead to Improved Blood Sugar
Read More
What Will It Take to Achieve Value From Digitally Enabled Diabetes Care?
A report from the Peterson Health Technology Institute (PHTI) found that many digital diabetes management platforms aren’t providing meaningful ROI for patients or the health system as a whole. Users of common technologies only see small, incremental clinical benefits, such as 0.23%–0.60% point reduction in HbA1c when compared to traditional care. Meanwhile, some health plans and employers are actually seeing an increase in overall costs as spending on these platforms can often
Read More
CCS Unveils AI Predictive Model to Predict & Improves CGM Adherence in Diabetes Management
What You Should Know:
- CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their
Read More
Nearly 70% of High-Risk Patients Unaware of Chronic Kidney Disease Risk, Study Finds
What You Should Know:
- A new study by Phreesia and the National Kidney Foundation (NKF) reveals a troubling gap in awareness of chronic kidney disease (CKD) among high-risk patients. Published in The American Journal of Accountable Care, the research highlights the importance of patient-provider communication and patient activation in early detection and prevention of CKD, a leading cause of death in the United States.
- The research emphasizes the value of patient education and
Read More
Tandem Mobi Insulin Pump Now Compatible with Dexcom G7 CGM
What You Should Know:
- Tandem Diabetes Care announced today that its Tandem Mobi insulin pump is fully compatible with Dexcom G6 and Dexcom G7 Continuous Glucose Monitoring (CGM) systems.
- Tandem is now the only company offering two insulin pump options integrated with both Dexcom G6 and Dexcom G7 CGM systems. This choice empowers people with diabetes to select the best solution for their individual needs and preferences.
Tandem Mobi: A Compact and Effective
Read More
Tandem Mobi Integrates with Dexcom G7 CGM, Expanding Choice for Diabetes Management
What You Should Know:
- Tandem Diabetes Care (TNDM) and Dexcom (DXCM) announced today that the Tandem Mobi insulin pump with Control-IQ technology is now compatible with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) systems.
- Overall, the Tandem Mobi and Dexcom G7 combination empowers people with diabetes with a discreet, convenient, and technologically advanced solution for managing their condition.
Tandem Mobi: Small Pump, Big Choice for Diabetes
Read More
Weekly Ozempic/Wegovy Injections May Lower Kidney Failure Risk, Study Finds
What You Should Know:
- A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 diabetes and chronic kidney disease (CKD).Find semaglutide online today.
- Funded by Novo Nordisk creators of Ozempic and Wegovy semaglutide injections for diabetes management, the study published in The New England Journal of Medicine investigated
Read More
Remote Diabetes Monitoring: Senseonics Partners with Rimidi to Enhance Diabetes Care
What You Should Know:
- Senseonics Holdings, Inc., a provider of long-term implantable continuous glucose monitoring (CGM) systems, today announced a strategic partnership with Rimidi. Rimidi offers a comprehensive clinical management platform designed to improve chronic disease management for patients and healthcare providers.
- The collaboration aims to develop the Eversense® Remote Patient Monitoring (RPM) Program, which will integrate seamlessly with existing healthcare
Read More
